Sun Pharma Q1 Results: Domestic Pharma & CDMO Stocks Stay In Focus Amid Strong Growth Outlook

Sun Pharma delivered steady quarterly performance, supported by strong domestic growth and a resilient specialty business, even as challenges remain in the US generics market. Pankaj Pandey, Head of Research, ICICI Direct, believes domestic-focused pharma companies and CDMO players offer better long-term opportunities than firms heavily dependent on US markets. He remains positive on companies with strong chronic therapy portfolios and highlights select pharma names benefiting from healthy demand and consistent earnings growth.